The Clinical Advisor You Just Recruited Has No Idea How to Get You Paid

You found the perfect clinical advisor. Department chair at a major academic medical center, twenty years of published research in exactly your disease area, genuinely excited about your technology. They showed up to your first advisory board meeting with notes. Real notes, on paper.

Photo by Tima Miroshnichenko on Pexels.

Great. You're still going to run out of money.

Here's the problem nobody warns you about when you're assembling your early clinical team: deep domain expertise and reimbursement fluency are two completely different skill sets. Most clinicians, even the brilliant ones, have never spent a single hour thinking about how a new procedure gets paid for. They order tests. Someone else handles the billing. That gap will cost you.

Reimbursement is where most medical device and diagnostics startups actually die. Not in the lab. Not in clinical trials. After clearance, when the hospital CFO asks a simple question: "What code do you bill under?" and your clinical advisor looks at the ceiling.

Why Clinicians Are Structurally Blind to This

Academic physicians operate in a world where coverage decisions are someone else's problem. A researcher developing a novel imaging technique thinks about sensitivity, specificity, and publication impact. Whether that technique will ever get a Category I CPT code, or survive payer medical policy review, or clear the "clinical utility" bar that CMS actually cares about: those questions live in a different building, handled by different people, measured in different units.

When you recruit a clinician to your advisory board, you are hiring their clinical judgment and their network. Those things are valuable. What you are not hiring, usually, is any practical understanding of how payers decide to cover new technologies, what evidence threshold Medicare Administrative Contractors will actually require, or why a "Category III" CPT code is a commercial death sentence for most device companies.

Your advisor may not even know what a MAC is.

The Conversation That Reveals Everything

Try this. In your next advisor meeting, ask: "If a community hospital purchases our device tomorrow, what happens when they try to bill for using it?" Watch the answer carefully.

A clinician with real reimbursement awareness will start talking about existing codes, off-label billing risk, potential for a new technology add-on payment under the NTAP program, or the gap between technical and professional components. They'll mention payer mix and ASP implications.

A clinician without it will tell you the procedure is medically necessary. That clinicians will want to use it. That the evidence is compelling.

Both of those things can be true. Neither of them pays for the device.

What You Actually Need in the Room

You need a reimbursement strategist involved before you finalize your clinical trial design. Not after clearance. Before. The evidence you generate has to match what payers will ask for, not just what reviewers at your target journal care about. Those requirements diverge more than founders expect.

If you cannot afford a full-time regulatory and reimbursement hire (you can't, yet), at minimum get one hour with a health economics consultant who has worked specifically on coverage submissions. Ask them to map your likely path:

graph TD
    A[De Novo or 510k Clearance] --> B{Existing billing code?}
    B -- Yes --> C(Validate payer coverage policies)
    B -- No --> D[Pursue new CPT code or unlisted]
    C --> E{Covered by major payers?}
    E -- Yes --> F(Commercial launch)
    E -- No --> G[Coverage with Evidence Development]
    D --> G
    G --> F

That map will tell you more about your real go-to-market timeline than anything your clinical advisors have said.

How to Fix Your Advisory Board Without Firing Anyone

You do not need to replace your clinical advisor. You need to add a different kind of voice to the room. Specifically: someone who has sat on the payer side of a coverage determination meeting, or a health economist who has built a cost-effectiveness model that actually influenced a formulary decision.

Also, brief your existing advisors on reimbursement basics before they speak to customers. Walk them through the CPT code situation. Explain what "coverage" actually means operationally. A good clinical advisor will absorb this fast. They are smart people. They just were never trained to think about it.

When a hospital VP of Surgery asks your advisor about reimbursement at a demo and your advisor says "I believe the company has a plan for that," you have a problem. Train them to say something specific, even if that something is: "We're currently working with payers on a Category I code submission and have interim billing guidance ready for early adopters." That is a real answer. It signals that someone in the company understands the path.

Your clinical advisor's job is to vouch for the science and open doors. Your job is to make sure that when those doors open, you have a revenue model waiting on the other side.